-
屈昔多巴_CAS：23651-95-8
编号：SH-NF-729 CAS：23651-95-8纯度：95%颜色：未知储存条件：干燥密封冷藏运输方式：普通
- 参数
- 详情
- 图片
商品信息
| 货号： | SH-NF-729 |
|---|---|
| CAS号： | 23651-95-8 |
| 商品名称 | 屈昔多巴 |
| 英文名称： | droxidopa |
| 纯度： | 98% |
| 分子式： | C9H11NO5 |
| 外观性状： | 未知 |
化合物百科
屈西多巴名称
| [ 中文名 ]: | 屈昔多巴 |
|---|---|
| [ 英文名 ]: | droxidopa |
| [中文别名 ]: | (-)-(2S,3R)-2-氨基-3-羟基-3-(3,4-二羟基苯基)丙酸 屈西多巴 (2S,3R)-2-氨基-3-(3,4-二羟基苯基)-3-羟基丙酸 |
| [英文别名 ]: | (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic acid DL-DOPS DL-threo-Dihydroxyphenylserine L-DOPS 3-dihydroxy-betthreo-dl-tyrosin (2S,3R)-3-(3,4-Dihydroxyphenyl)-2-amino-3-hydroxypropanoic acid 3-dihydroxy-dl-tyrosinethreo-bet DROXIDOPA (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid Benzeneethanaminium, α-carboxy-β,3,4-trihydroxy-, inner salt, (αS,βS)- (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-threo-DOPS DL-THREO-DOPS L-threo-3,4-Dihydroxyphenylserine (2S,3S)-2-Ammonio-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Droxidopa L-threo 3,4-Dihydroxyphenylserine DL-threo-Droxidopa threo-Dopaserine L-threo-3-(3,4-Dihydroxyphenyl)serine |
屈西多巴物理化学性质
| [ 密度 ]: | 1.608g/cm3 |
|---|---|
| [ 沸点 ]: | 549.8±50.0 °C at 760 mmHg |
| [ 分子式 ]: | C9H11NO5 |
| [ 分子量 ]: | 213.187 |
| [ 闪点 ]: | 286.3±30.1 °C |
| [ 精确质量 ]: | 213.063721 |
| [ PSA ]: | 124.01000 |
| [ LogP ]: | -0.95 |
| [ 蒸汽压 ]: | 0.0±1.6 mmHg at 25°C |
| [ 折射率 ]: | 1.692 |
| [ 分子结构 ]: | 1、 摩尔折射率：50.79 2、 摩尔体积（cm3/mol）：132.5 3、 等张比容（90.2K）：417.2 4、 表面张力（dyne/cm）：98.2 5、 极化率（10-24cm3）：20.13 |
| [ 更多 ]: | 1.性状：从乙醇和乙醚结晶，白色至淡褐色结晶或结晶性粉末，无臭无味 2.熔点（℃）：232-235(分解)。 3.比旋光度(C=1，lmo1/L盐酸)：-39。 4.溶解度：溶于稀盐酸，难溶于水，几不溶于甲醇、乙醇、冰醋酸、丙酮、氯仿或乙醚。 |
屈西多巴MSDS
模块1. 化学品 Droxidopa 模块2. 危险性概述 模块3. 成分/组成信息 模块4. 急救措施 模块5. 消防措施 模块6. 泄露应急处理 模块7. 操作处置与储存 模块8. 接触控制和个体防护 模块9. 理化特性 模块10. 稳定性和反应活性 模块11. 毒理学资料 模块12. 生态学资料 模块13. 废弃处置 模块14. 运输信息 模块16. 其他信息 模块 15 - 法规信息 |
屈西多巴毒性和生态
屈西多巴毒理学数据:
急性毒性LD50大鼠和小鼠(rng/kg)：＞10000口服。急性毒性LD50狗和恒河猴(mg/kg)：＞5000口服。
CHEMICAL IDENTIFICATION
RTECS NUMBER :
VT9626010
CHEMICAL NAME :
Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-
CAS REGISTRY NUMBER :
23651-95-8
LAST UPDATED :
199603
DATA ITEMS CITED :
12
MOLECULAR FORMULA :
C9-H11-N-O5
MOLECULAR WEIGHT :
213.21
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,758,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
84 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,758,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
16 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - ataxia Lungs, Thorax, or Respiration - other changes
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 2),257,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,758,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>10 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,758,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>100 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,758,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Cardiac - other changes Lungs, Thorax, or Respiration - dyspnea Kidney, Ureter, Bladder - other changes
REFERENCE :
YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 40,1935,1989
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Cardiac - other changes Lungs, Thorax, or Respiration - respiratory depression Kidney, Ureter, Bladder - other changes
REFERENCE :
YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 40,1935,1989 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
13200 mg/kg
SEX/DURATION :
female 15 day(s) pre-mating female 1-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 2),283,1987
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2200 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.
0
